SPOTLIGHT: Merck scraps AIDS vaccine
Over the weekend Merck announced that it was scrapping development of a promising AIDS vaccine after researchers concluded that it had failed a large international study. This was considered a major setback in the effort to develop an AIDS vaccine. In the trial, 24 volunteers receiving the vaccine contracted AIDS compared to 21 in the control group. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
